Replies to post #213931 on Biotech Values

[DewDiligence]

ADXS—rather than AMGN—has responsibility for ADXS-NEO manufacturing; from the 10-K (page 13):

https://www.sec.gov/Archives/edgar/data/1100397/000149315217000250/form10-k.htm

Under the Amgen Agreement, Amgen will fund the clinical development and commercialization of ADXS-NEO and Advaxis will retain manufacturing responsibilities.

Would that it weren't so. The fact that ADXS subcontracted some of the work to Synthetic Genomics doesn't mean it wasn't a mistake for ADXS to retain manufacturing responsibility.